A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

1. Age: 18-75 years old, both genders are eligible.
2. Pathological Diagnosis: Histologically confirmed soft tissue sarcoma, including but not limited to:

   * Undifferentiated pleomorphic sarcoma
   * Liposarcoma
   * Leiomyosarcoma
   * Synovial sarcoma
   * Fibrosarcoma
   * Other high-grade soft tissue sarcomas
3. Disease Stage:

   * Locally advanced, unresectable soft tissue sarcoma, or
   * Recurrent or metastatic soft tissue sarcoma
4. Prior Therapy:

   * Prior surgery, radiotherapy, or chemotherapy is allowed.
   * At least 4 weeks since the last anti-tumor treatment.
   * Prior treatment-related toxicities have resolved to ≤Grade 1 (except alopecia).
5. Measurable Disease: At least one measurable lesion according to RECIST 1.1 criteria.
6. Performance Status: ECOG performance status score of 0-2.
7. Life Expectancy: ≥3 months.
8. Organ Function:

   * Hematology: Hemoglobin ≥50 g/L, absolute neutrophil count ≥1.5×10⁹/L, platelet count ≥60×10⁹/L
   * Liver Function: Total bilirubin ≤1.5× upper limit of normal (ULN), ALT and AST ≤2.5× ULN (≤5× ULN for patients with liver metastasis)
   * Renal Function: Serum creatinine ≤1.5× ULN or creatinine clearance ≥50 mL/min
   * Cardiac Function: Left ventricular ejection fraction ≥40%
9. Informed Consent: The patient or their legal representative has signed the informed consent form.

Exclusion Criteria:

1. Special Types of Sarcoma:

   * Gastrointestinal Stromal Tumor (GIST)
   * Osteosarcoma
   * Ewing's Sarcoma
2. Prior Treatment History:

   * Previous radiotherapy to the same site with a cumulative dose that may exceed the normal tissue tolerance dose
   * Major surgery within 4 weeks
3. Concurrent Diseases:

   * Active autoimmune diseases
   * Diseases requiring systemic immunosuppressive therapy
   * Severe cardiovascular diseases (myocardial infarction, unstable angina, heart failure, etc.)
   * Severe pulmonary diseases (interstitial pneumonia, pulmonary fibrosis, etc.)
   * Active infections requiring systemic anti-infective therapy
4. Central Nervous System Metastasis: Symptomatic brain or spinal metastasis.
5. Pregnancy and Lactation: Women who are pregnant or breastfeeding.
6. Allergy History: Known allergies to the drugs or their components involved in the study.